H-HeFT missed its primary endpoint, but the accompanying meta-analysis adds important context.
X post ↗What happened
Hydralazine-isosorbide dinitrate linked to ~29% lower all-cause death in heart failure patients.
H-HeFT missed its primary endpoint, but the accompanying meta-analysis adds important context.
X post ↗Pooled trials show hydralazine-isosorbide dinitrate cut all-cause death by 29% and CV death by 35% in HFrEF.
X post ↗She reports that H-HeFT, which tested H-ISDN in a broader contemporary HFrEF population, was neutral on its primary endpoint (HR 0.90, 95% CI 0.67–1.21).
X post ↗Open questions from this trial that would benefit from expert input.
Why the trial, tables, limitations, PICO, abstract, media & sources
Randomised trials of hydralazine-isosorbide dinitrate in heart failure span five decades and differ in populations and background therapy. Pooling them clarifies whether the combination reduces mortality across historical and contemporary settings.
Does hydralazine-isosorbide dinitrate reduce mortality in patients with heart failure with reduced ejection fraction?
Does hydralazine-isosorbide dinitrate reduce mortality in patients with heart failure with reduced ejection fraction?
Early expert posts mostly report the pooled survival benefit of hydralazine plus isosorbide dinitrate and set it against the neutral result of the new H-HeFT trial, and no one has yet said it should change practice.
Clinicians posting from the congress are mainly passing on the headline finding that the pooled trials point to fewer deaths with this drug combination. Several of them pair it with the companion H-HeFT trial, which did not meet its main goal on its own, and present the pooled analysis as context for that result. Nobody has openly disagreed so far, and the open question is how much weight the pooled signal can bear when the trials differed so much.
Three clinicians agree that the H-HeFT trial on its own did not significantly reduce its primary endpoint. This is the backdrop they use when reading the pooled analysis.
The heart failure hospitalisation finding is reported in different ways. One clinician's slide summary lists a significant reduction in first HF hospitalization, but the investigators called hospitalisation results inconsistent across trials. None of the posts says whether the pooled survival signal should change how this combination is used outside the populations studied before.
Although hydralazine-isosorbide dinitrate is associated with reduced all-cause and cardiovascular mortality in HFrEF, significant trial heterogeneity and tolerability issues prevent firm clinical conclusions.
This meta-analysis pooled three randomised trials of hydralazine-isosorbide dinitrate in heart failure, including A-HeFT and H-HeFT, covering 2,101 patients. H-ISDN was associated with a reduction in all-cause death (HR 0.71, 95% CI 0.58 to 0.87) and cardiovascular death (HR 0.65, 95% CI 0.47 to 0.90), while results for heart-failure hospitalisation were inconsistent across trials. Substantial differences in trial design, duration of follow-up and background therapy were noted. Presented in Hot Line 6 at ESC Congress 2026, the investigators concluded that given the heterogeneity and the tolerability issues it is difficult to make firm conclusions about the effect of H-ISDN on cardiovascular outcomes. Source: ESC Congress 2026 press release, 30 August 2026.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
Morten Schou (2026) conducted a meta-analysis in Heart failure with reduced ejection fraction (n=2,101). Hydralazine-isosorbide dinitrate (H-ISDN) was evaluated on All-cause death (HR 0.71, 95% CI 0.58-0.87). Hydralazine-isosorbide dinitrate was associated with a reduction in all-cause death and cardiovascular death.
Synapse has enriched 10 related papers. Consider them for comparative context: